Form 4: Supernus Pharmaceuticals Director Frederick M. Hudson Reports Transaction
SEC Form 4 Filing
Director Frederick M. Hudson reports a transaction involving Supernus Pharmaceuticals common stock and restricted stock units.
Summary
- On February 23, 2024, Frederick M. Hudson, a director of Supernus Pharmaceuticals, engaged in a transaction involving the company's securities.
- Hudson acquired 3,886 shares of common stock at $0.
- Hudson disposed of 3,886 restricted stock units, which vested on the same date and were settled in common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction by a company director, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The transaction may provide stakeholders with insights into the director's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of transaction: acquisition of common stock and disposal of restricted stock units. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.